FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which was reported in June 2025, the company looks forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
Cyborg Score Rationale
Forte Biosciences has surged over 130% since November 2025 in anticipation of 2026 data for FB102 in celiac, vitiligo, and alopecia areata. However, FBRX trades at a $350M+ premium to cash, with no expected sales until 2030 and profitability forecast for 2033. The company has secured runway through capital raises.
Top Insights
The company held $58.2 million in cash at March 31, 2026 and subsequently raised $172.5 million in gross proceeds in an April 2026 equity offering
Net loss of $22.1 million in Q1 2026 (up from $15.7 million a year earlier), driven mainly by higher R&D spending which rose to $20.5 million, largely from FB102 Phase 2 celiac disease and Phase 1b vitiligo and alopecia areata trials
FB102 showed statistically significant Phase 1b celiac results but faces a crowded competitive landscape with 14+ rival programs in development
Despite enthusiasm for FB102 as a 'pipeline in a product,' modest symptom relief and IV administration limit near-term commercial appeal
Named Competitors
Immunology therapeutics (autoimmune targets) — Established immunology and autoimmune disease therapies
Autoimmune and inflammatory therapeutics — Large-cap biotech with extensive autoimmune portfolio
Clinical-stage immunology programs — Clinical-stage competitor in autoimmune space
Recent Developments
(April 2026) Raised $172.5 million in gross proceeds through equity offering at $26.27 per share
(May 2026) Announced Q1 2026 results with $22.1 million net loss and achieved FDA Fast Track Designation for FB102 in celiac disease